AbbVie forms two oncology-focused collaborations with CytomX and argenx
AbbVie and CytomX will jointly develop and commercialize probody drug conjugates directed against CD71, which is highly expressed several solid and hematologic cancers. Under the deal, CytomX will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.